IsoRay, Inc. Announces Its Addition To The Russell Microcap Index

RICHLAND, WA--(Marketwired - June 30, 2014) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for cancers of the brain, lung, head and neck, prostate and gynecologic (“gyn”), today announced that it has been added to the Russell Microcap Index.

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective market-capitalization rankings and style attributes.

IsoRay Chairman and CEO Dwight Babcock commented, “Being included in the Russell Microcap Index represents an important milestone for IsoRay that we expect will increase shareholder awareness of our accomplishments. This follows several other recent milestones for IsoRay, including our newest product, Liquid Cesium-131, being FDA cleared, our first patient being treated using GliaSite with liquid cesium-131 and a peer reviewed publication on the success of using IsoRay’s Cesium-131 seed in treating gynecologic cancers.”

About Russell

Russell Investments (Russell) is a global asset manager and one of only a few firms that offer activity managed multi-asset portfolios and services that include advice, investments and implementation. Russell stands with institutional investors, financial advisers and individuals working with their advisers -- using the firm’s core capabilities that extend across capital market insights, manager research, portfolio construction, portfolio implementation and indexes to help each achieve their desired investment outcomes.

About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which
is expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington
company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join
us on Facebook/Isoray. Follow us on Twitter@Isoray.

Safe Harbor Statement
Statements in this news release about IsoRay’s future expectations, including: the advantages of our products and their delivery systems, whether inclusion of IsoRay in the Russell Microcap Index will increase shareholder awareness of IsoRay’s accomplishments, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of IsoRay’s products, changing levels of demand for IsoRay’s current and proposed future products, IsoRay’s ability to reduce or maintain expenses while increasing sales, whether additional studies are released and support the conclusions of past studies, patient results achieved with our products, successful completion of future research and development activities, our ability of our distributors and customers to receive and maintain all required regulatory approvals in the U.S. and internationally, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, IsoRay’s ability to successfully manufacture, market and sell its products, whether institutions will receive all required state, federal and foreign regulatory approvals and licenses to use IsoRay’s products, IsoRay’s ability to manufacture its products in sufficient quantities to meet demand within required delivery time periods while meeting its quality control standards, IsoRay’s ability to enforce its intellectual property rights, changes in reimbursement rates, changes in laws and regulations applicable to our products, whether IsoRay will continue to be included in the Russell Microcap Index, and other risks detailed from time to time in IsoRay’s reports filed with the SEC.